Xeris granted ODD for investigational ready-to-use liquid glucagon by EMA

Xeris Pharmaceuticals announced that it has received Orphan Medicinal Product designation from the European Medicines Agency for its investigational ready-to-use liquid glucagon as a treatment for non-insulinoma pancreatogenous hypoglycaemia syndrome, a spectrum of metabolic conditions, which includes post-bariatric hypoglycemia. A similar orphan designation was granted by the FDA in January 2018. The EU orphan designation is associated with a 10-year commercial exclusivity for this indication.
https://thefly.com/landingPageNews.php?id=2839949